Chronic Lymphocytic Leukemia

CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR

HEADLINES
DRUG INFORMATION

FEATURED CONTENT

How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia

Experts outline treatment options for patients with venetoclax resistance.
Data From the CAPTIVATE Study’s uMRD Cohort Suggest Role for Fixed-Duration Therapy in CLL/SLL [Q&A]

John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.
Four-Factor CLL Prognostic Score Deemed Clinically Useful for Risk Classification

Risk-stratification technology is evolving in chronic lymphocytic leukemia and can be used to guide treatment decisions and direct patients to clinical trials.
Triple Therapy for CLL Shows Promise in Phase 2 Trial

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.
Targeted Molecular Therapies for the Treatment of Chronic Lymphocytic Leukemia

Researchers reviewed promising advances in therapy options for patients with CLL and the challenges associated with these new treatments.

CHRONIC LYMPHOCYTIC LEUKEMIA NEWS

Venetoclax and ibrutinib are therapeutic agents for CLL.

Venetoclax and Obinutuzumab ± Ibrutinib Bests Chemoimmunotherapy in CLL

May 16, 2023

Brukinsa Gains Approval for Chronic Lymphocytic Leukemia

January 23, 2023

Image of patient holding white capsules.

Zanubrutinib Outperforms Ibrutinib in Relapsed/Refractory CLL/SLL

December 19, 2022

Pharmacist giving a medicine bottle to patient

Zanubrutinib May Produce Better Outcomes Than Ibrutinib in Rel/Ref CLL, SLL

November 29, 2022

Blue and white capsules in a blister pack

Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers

November 15, 2022

Next post in Chronic Lymphocytic Leukemia

Brukinsa Gains Approval for Chronic Lymphocytic Leukemia